The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies.   The report provides a detailed understand and analysis of how and why companies enter co-development deals.   Understanding the flexibility of a prospective more »

The Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.   The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals.   Understanding the more »

The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.   The report provides a detailed understand and analysis of how and why companies enter licensing deals.   Understanding the flexibility of a more »

The Big pharma Deals and Alliances Review report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during the past year.

The Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

The Drug Delivery Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the drug delivery partnering agreements entered into by the worlds leading companies. 

The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the worlds leading biopharma companies.

The Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies.

The Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals. The majority of deals are acquisitions whereby the acquirer acquires the target company in a cash and/or equity transaction.

NPS Pharmaceuticals is a US based specialty company. The company mainly focuses its efforts to treat rare diseases worldwide. 

SciClone Pharmaceuticals is a US based specialty company. The company focusses its efforts to widen its portfolio in China by in-licensing and acquiring rights to marketed products.

Big biotech or bigbiotech is the collective name given to the top biotechnology companies in the world ranked by global sales of prescription drugs

Partnering trends and deal analysis reviewed with over 4,000 deals entered by the world’s leading fifty big pharma and big biotech companies

The big biotech rumor mill gives idea that a changing of the guard at Switzerland’s two biggest drugmakers means that Novartis may finally sell its multi-billion-dollar stake in cross-town rival Roche, potentially unlocking value for both sets of shareholders.

Perhaps it’s no surprise that much of the top venture investment for the first half of 2012 was delivered by the VC arm of billionaire Randal Kirk to his big biotech venture Intrexon

Celgene, a big biotech/pharma company is not buying Human Genome Sciences, according to a source in contact with Celgene management

Xconomy examines Alkermes’ new company strategy in the wake of its acquisition of Elan Drug Technologies. The EDT buyout, explains Luke Timmerman, gives the biotech a steady revenue flow to build on with some prospective upside from products like Bydureon. 

High profile Frederick Frank has assessed the playing field for Sanofi-Aventis’ $18.5bn offer for Genzyme and concluded that the big biotech company “is history”.

Biotech rumour mill: If AstraZeneca, a big pharma company, decides it needs a big acquisition to get out of the doldrums, it may find itself competing with Bristol-Myers Squibb

Leidos was awarded a pharma deal with prime contract by the U.S. Defense Threat Reduction Agency to conduct research and development to combat weapons of mass destruction.

Catalent Pharma Solutions announced an agreement with the Center for iPS Cell Research and Application at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Definiens and Metamark Genetics announced a multi-year agreement covering use of the Definiens image analysis solution for the ProMark.

Attendance is limited to 75 participants to ensure the optimal instructor/student ratio and quality interaction. 

China-based, CASI has signed a licensing agreement with big biotech, Spectrum Pharma’s for its products: Zevalin, Marqibo and Melphalan.

Big biotech, Emergent BioSolutions has signed a contract with the National Institute of Allergy and Infectious Diseases to develop a dry formulation of NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant).

Alnylam Pharmaceuticals and The Alpha-1 Project have entered into a collaboration agreement for the continued advancement of ALN-AAT.

M&A news : Big biotech company, Emergent BioSolutions will acquire Cangene in an all-cash transaction valued at US$222 million

The Medicines Company has acquired Rempex Pharmaceuticals for $474 million

Enzo Biochem, big biotech, enters into marketing agreement with Sequenom Laboratories for MaterniT21 PLUS

Adimab announced a multi-target discovery biotech deals collaboration with Celgene Corporation.

Onyx Pharmaceuticals, a big biotech company, has entered pharma deals with IDIS Pharma for Multiple Myeloma treatment.

Acorda Therapeutics has entered biotech deals with NeurogesX for two neuropathic pain management assets .

SciClone Pharmaceuticals enters biotech deals with Taiwan Liposome granting SciClone a licensing and exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell ProFlow.